ClinicalTrials.gg

Program

TQB3122

A development code. Also written as “TQB3122 Capsules”.

In Sino Biopharmaceutical's pipeline, PARP1抑制剂. Its studies are led by Sino Biopharmaceutical.

Furthest: phase 1, since Nov 26, 20251 company-led study, 1 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 1since Nov 26, 2025Nov 26, 2025Dec 2026phase 1 · NCT07269145
  • Named in Sino Biopharmaceutical’s own pipeline as TQB3122, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 26, 2025First study: phase 1 study in Advanced CancerFirst studyNCT07269145 · 86 planned · China

Ahead

  1. Dec 2026Primary completion: phase 1 study in Advanced CancerNCT07269145

TargetBeta

“PARP1抑制剂”the company's pipeline, read by Claude · source

Other programs on PARP1

ProgramCompanyFurthest phaseStudies
olaparibruleAstraZenecaphase 478
niraparibruleGlaxoSmithKlinephase 443
saruparibruleAstraZenecaphase 314
senaparibruleimpact-therapeutics-incphase 212
nesuparibruleJeil Pharmaceuticalphase 24
palacaparibAstraZenecaphase 23
PARP1 Inhibitor HS-10502ruleHansoh Pharmaceutical Groupphase 12
DM5167ruledigmbiophase 11
HSK46256ruleHaisco Pharmaceutical Groupphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07269145Advanced Cancer · China1RecruitingDec 202686

How it is read

Names in the registry

  • “TQB3122 Capsules”, 1 entry

Codes read as this program: TQB3122.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.